ACTRN12612000263897进行中（未招募）3 期
A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus 2N(t)RTI in antiretroviral-naive HIV-infected individuals over 96 weeks. Encore1 intensive pharmacokinetics sub-study
Kirby Institute/University of New South Wales0 个研究点目标入组 40 人开始时间: 2012年3月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •Main study participants at selected sites are eligible:
- •provide written sub-study consent at or before week 0
- •taken randomized study drugs for at least 4 weeks but less than 8 weeks
- •taken EFV in the evening for at least 7 days
- •taken all EFV doses over the 3 preceding days.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhibitors (N(t)RTI) in antiretroviral-naïve HIV-infected individuals over 96 weeks. - Encore1HIV infectionMedDRA version: 14.0 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2009-013795-44-GBational Centre in HIV Epidemiology and Clinical Research630
进行中（未招募）
3 期
A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhibitors (N(t)RTI) in antiretroviral-naïve Human Immunodeficiency virus (HIV)-infected individuals over 96 weeks.HIV infectionInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12610001097033ational Centre for HIV Epidemiology and Clinical Research630
进行中（未招募）
不适用
A 96 week study comparing the standard dose (600mg) to the reduced dose (400mg) efavirenz with the combination of Truvada for HIV-infected participants who have not taken any anti-HIV medication.Human Immunodeficiency Virus infectionEUCTR2009-013795-44-DEThe Kirby Institute (formerly National Centre in HIV Epidemiology and Clinical Research (NCHECR)), University of New Sou630
尚未招募
不适用
A clinical study to evaluate the safety and efficacy of ABE-0520 on middle-aged male subjects with androgen deficiencyCTRI/2021/01/030391Akay Natural Ingredients Pvt Ltd
尚未招募
不适用
Effect of CUQ1720 on blood glucose level after the food on healthy volunteers and diabetes patientsCTRI/2020/03/023947Akay Flavours and Aromatics Private Limited